FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Zocor | Merck | Generics | shareholders

SPOTLIGHT: Merck sees Zocor sales drop

Tools

SPOTLIGHT... Merck sees Zocor sales drop
While reporting an increase in profit and a dip in drug sales for the third quarter, new Merck CEO Richard Clark is promising shareholders that he will unveil a long-term recovery plan for the drug maker by the end of the year. Merck has seen a significant slip in sales of Zocor, which is facing increased generic competition in the cholesterol-lowering category. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Zocor   Merck   Generics   shareholders